1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Skin Cancer Vaccine Market & Pipeline Insight 2015

Global Skin Cancer Vaccine Market & Pipeline Insight 2015

  • February 2015
  • 178 pages
  • ID: 4397235
  • Format: PDF
  • By Kuick Research

Summary

Table of Contents

Skin cancer incidences are increasing at alarming rates across the world causing high morbidity and mortality. Research and development in field is expected to change the present scenario by providing better therapeutic options for patients. Skin cancer therapeutics available in market used for first-line treatment have modest efficacy which lays emphasis on the development of better products like skin cancer vaccines. Cancer vaccines for different disease indications have proved their worth in medical fraternity by providing better safety and efficacy profiles. Skin cancer vaccines based products are not available in market but they are soon expected to be entering in market in coming years. Market introduction of such products is much awaited to fulfill the unmet medical demand.

Skin cancer vaccine category seems to be one of the most advanced drug category in terms of number of products and types of products. Efforts in this field have allowed the investigators to come with new ideas like implants and oncolytic viruses for the treatment of skin cancer. Such dichotomy is not observable in other cancer categories due to which this segment is expected to occupy significant market share. Also, among different cancer products this skin cancer is expected to generate more revenues in coming years. Initially, it is expected that skin cancer vaccines would be used in combinatorial therapy with conventionally available drugs before becoming main stream treatment. Owing to better pharmacological profiles they are expected to become regular component of therapeutic regime.

Novelty of skin cancer vaccine design is expected to be the major factor in increasing their market penetration. Oncolytic skin cancer vaccines are much awaited products as they have no competitors in present market. Theoretically, they can cure skin cancer at advanced stages and increase the life span of patients but they still needs to be investigated rigorously in clinical trials before market introduction. Skeptics and many medical professional show concern about use of oncolytic viruses as they have pathogenic background and mutate to wild type causing infection in patients. However, such phenomenon has not been observed due to advanced genetic engineering and strict quality control during skin cancer vaccine production. Some of these products are at advanced phases of clinical trials meeting predefine end points for qualifying as a viable pharmacological option.

Implant section of skin cancer vaccine is also expected to make significant impact by decreasing present mortality and morbidity rates. Concept and therapeutic products using implants for treatment has been in pharmaceutical market for several decades. They tend to be more comfortable, require less visits to physicians and higher cost arbitrage coupled with improved technological advancements. This gives a notion that skin cancer vaccines implants will get higher acceptance rates as compared to oncolytic virus based products. However, it should not be compared in case of pharmacological effects because this depends on patients’ medical condition and oncologists’ discretion to utilize best product according to necessity.



“Global Skin Cancer Vaccine Market & Pipeline Insight 2015” Report Highlight

Introduction to Skin Cancer Vaccine
Global Skin Cancer Vaccine Market Analysis
Global Skin Cancer Vaccine Pipeline by Company & Phase
Global Skin Cancer Vaccine Pipeline: 47 Vaccines
Majority Skin Cancer Vaccines in Phase-I: 12 Vaccines
Marketed Skin Cancer Vaccines: 2 (MVax by AVAX Technologies & Melacine by GlaxoSmithKline)
Personalized Cancer Vaccines: Progress & Possibilities
Skin Cancer Vaccine Mechanism

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Rotavirus Infections - Pipeline Review, H2 2019

Rotavirus Infections - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Rotavirus Infections - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H2 2019, provides an overview of the Rotavirus ...

Ragweed Pollen Allergy - Pipeline Review, H2 2019

Ragweed Pollen Allergy - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Ragweed Pollen Allergy - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Ragweed Pollen Allergy - Pipeline Review, H2 2019, provides an overview of the Ragweed ...

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2019

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, ...


ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on